Logo

Log In Sign Up |  An official publication of: American College of Emergency Physicians
Navigation
  • Home
  • Multimedia
    • Podcasts
    • Videos
  • Clinical
    • Airway Managment
    • Case Reports
    • Critical Care
    • Guidelines
    • Imaging & Ultrasound
    • Pain & Palliative Care
    • Pediatrics
    • Resuscitation
    • Trauma & Injury
  • Resource Centers
    • mTBI Resource Center
  • Career
    • Practice Management
      • Benchmarking
      • Reimbursement & Coding
      • Care Team
      • Legal
      • Operations
      • Quality & Safety
    • Awards
    • Certification
    • Compensation
    • Early Career
    • Education
    • Leadership
    • Profiles
    • Retirement
    • Work-Life Balance
  • Columns
    • ACEP4U
    • Airway
    • Benchmarking
    • Brief19
    • By the Numbers
    • Coding Wizard
    • EM Cases
    • End of the Rainbow
    • Equity Equation
    • FACEPs in the Crowd
    • Forensic Facts
    • From the College
    • Images in EM
    • Kids Korner
    • Medicolegal Mind
    • Opinion
      • Break Room
      • New Spin
      • Pro-Con
    • Pearls From EM Literature
    • Policy Rx
    • Practice Changers
    • Problem Solvers
    • Residency Spotlight
    • Resident Voice
    • Skeptics’ Guide to Emergency Medicine
    • Sound Advice
    • Special OPs
    • Toxicology Q&A
    • WorldTravelERs
  • Resources
    • ACEP.org
    • ACEP Knowledge Quiz
    • Issue Archives
    • CME Now
    • Annual Scientific Assembly
      • ACEP14
      • ACEP15
      • ACEP16
      • ACEP17
      • ACEP18
      • ACEP19
    • Annals of Emergency Medicine
    • JACEP Open
    • Emergency Medicine Foundation
  • About
    • Our Mission
    • Medical Editor in Chief
    • Editorial Advisory Board
    • Awards
    • Authors
    • Article Submission
    • Contact Us
    • Advertise
    • Subscribe
    • Privacy Policy
    • Copyright Information

Choice of Seizure Medication for Post-Stroke Epilepsy May Influence Survival

By Megan Brooks (Reuters Health) | on January 13, 2022 | 0 Comment
Latest News
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
Print-Friendly Version
For patients who develop epilepsy after suffering a stroke, the choice of antiseizure medication may influence their survival, according to a Swedish registry study.

You Might Also Like
  • New Recommendations Issued for Management of an Unprovoked First Seizure in Adults
  • Best Practices for Seizure Management In the Emergency Department
  • Follow-up Finds Clot Removal Offers Better Stroke Outcomes
“These findings suggest that there are differences in survival between specific antiseizure medications (ASMs) and that lamotrigine and levetiracetam seem to be reasonable first-line treatment options for patients with post-stroke epilepsy,” the study team writes in JAMA Neurology.

Stroke is the most commonly identified cause of new-onset epilepsy in adults. However, evidence to guide the choice of ASM in this population is lacking, and there are theoretical concerns about harmful effects of these medications on survival, Dr. David Larsson with Sahlgrenska University in Gothenburg and colleagues point out.

To explore whether mortality varies with specific ASMs in post-stroke epilepsy, they did a population-based cohort study of 2,577 patients (median age, 78; 54% men) who developed epilepsy after a stroke and were treated with a single ASM.

The results showed that patients treated with lamotrigine had a significantly lower risk of dying from cardiovascular and any cause compared with peers treated with carbamazepine.

Compared with carbamazepine, the adjusted hazard ratio for death from any cause was 0.72 (95% CI, 0.60 to 0.86) for lamotrigine, 0.96 (95% CI, 0.80 to 1.15) for levetiracetam, 1.40 (95% CI, 1.23 to 1.59) for valproic acid, 1.16 (95% CI, 0.88 to 1.51) for phenytoin and 1.16 (95% CI, 0.81 to 1.66) for oxcarbazepine.

Compared with carbamazepine, the adjusted hazard ratio for cardiovascular death was 0.76 (95% CI: 0.61 to 0.95) for lamotrigine, 0.77 (95% CI: 0.60 to 0.99) for levetiracetam, 1.40 (95% CI: 1.19 to 1.64) for valproic acid, 1.02 (95% CI: 0.71 to 1.47) for phenytoin, and 0.71 (95% CI: 0.42 to 1.18) for oxcarbazepine.

Lamotrigine had the highest three-year survival rate (0.62), followed by levetiracetam (0.55), oxcarbazepine (0.54), carbamazepine (0.53), valproic acid (0.34), and phenytoin (0.32).

In email to Reuters Health, Dr. Larsson said, “Persons with epilepsy after a stroke constitute a vulnerable group that benefit from tailored treatment. The selection of antiseizure medications depends on many factors, but on a group level, it seems reasonable to avoid drugs that may interfere with other drugs used to prevent stroke and heart disease.”

“There are no official treatment guidelines in this particular patient group, but our findings support what was previously suspected. Even before this study, most clinicians would recommend modern non-enzyme-inducing drugs, such as lamotrigine or levetiracetam, as first-line treatment options,” Dr. Larsson said.

Pages: 1 2 | Single Page

Topics: SeizureStroke

Related

  • Evidence Mounts Backing Rescue Ketamine for Prehospital Status Epilepticus

    April 30, 2025 - 0 Comment
  • ACEP Clinical Policy on Seizures

    April 23, 2025 - 0 Comment
  • ACEP Approves Clinical Policy on Seizures

    March 10, 2025 - 0 Comment

Current Issue

ACEP Now May 03

Download PDF

Read More

No Responses to “Choice of Seizure Medication for Post-Stroke Epilepsy May Influence Survival”

Leave a Reply Cancel Reply

Your email address will not be published. Required fields are marked *


*
*

Wiley
  • Home
  • About Us
  • Contact Us
  • Privacy
  • Terms of Use
  • Advertise
  • Cookie Preferences
Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 2333-2603